COMPANY PROFILE

Tryton Medical

Leading developer of novel stents, offers its proprietary Tri-ZONE technology as a dedicated strategy to treat, protect and secure bifurcations

Raleigh, United StatesFounded 2003Biotech & Life Sciences

Valuation $0–100M Latest valuation · 2017

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Tryton Medical

Tryton Medical is a pioneering company specializing in the development of advanced stent systems designed to treat bifurcation lesions in coronary arteries. Co-founded by Aaron V. Kaplan M.D. and H. Richard Davis, the company addresses a critical need in the treatment of coronary artery disease, particularly where plaque buildup occurs at the junction where a main artery splits into a smaller side branch artery. Approximately 25% of patients with coronary artery disease have such bifurcation lesions, making Tryton's solutions highly relevant.

Read full description

The company's flagship product, the Tryton Side Branch Stent, is engineered to treat a wide range of bifurcated lesions. This stent is deployed in the side branch artery using a standard single wire, balloon-expandable stent delivery system. Its open architecture allows for the integration of a conventional drug-eluting stent in the main vessel, ensuring complete lesion coverage. Tryton has conducted the largest randomized clinical trial comparing its stent system to a provisional stenting strategy, enrolling over 700 patients from up to 75 centers globally.

Tryton Medical primarily serves cardiologists and healthcare institutions specializing in cardiovascular treatments. Operating in the medical device market, the company's business model revolves around the sale of its stent systems, which are restricted to sale by or on the order of a physician as per Federal USA law. Revenue is generated through direct sales to hospitals and medical centers, as well as through partnerships with medical device distributors.

Source: Dealroom company data